Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28570110 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL1496715 | 0.98 | NPY1R (0.60) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL1496787 | 0.96 | NPY1R (0.57) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL1496809 | 0.93 | NPY1R (0.59) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL1496812 | 0.91 | NPY1R (0.58) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL20022643 | 0.90 | NPY1R (0.73) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL1496527 | 0.89 | NPY1R (0.55) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL20022639 | 0.86 | NPY1R (0.56) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL29428932 | 0.85 | ALDH1A1 (0.54) | NPY1RNPY2RNPY4RNPY5RALDH1A1 | |
| SCHEMBL11502967 | 0.85 | NPY1R (0.55) | NPY1RNPY2RNPY4RNPY5RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023127708-A1 | EPOXY RESIN COMPOSITION | 住友精化株式会社 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023127709-A1 | EPOXY RESIN COMPOSITION | 住友精化株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| EP-3820573-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| EP-1982972-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982973-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-6995110-B2 | Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20040077487-A1 | Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1210326-B1 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1380342-A1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6677355-B1 | DIBENZOFURAN-3-(SULFONYLAMINO OR SULFINAMINO) DERIVATIVES; MULTIPLE SCLEROSIS, ATHEROSCLEROSIS, HEART FAILURE, PERIODONTAL DISEASE, OSTEOARTHRITIS, AUTOIMMUNE DISEASE; ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1210326-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012592-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | NPY1R 2402/4885NPY2R 2319/4885NPY4R 3437/4885 |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | NPY1R 3410/4885NPY2R 4172/4885NPY4R 4575/4885 |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | NPY1R 10/4885NPY2R 12/4885NPY4R 90/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | NPY1R 10/4885NPY2R 12/4885NPY4R 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.